Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,564 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Regimen Clear all
Completed Phase 2 Interventional Results available

A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors

NCT05712356
View directory record Official record
Conditions
Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma
Interventions
certepetide, Durvalumab, Cisplatin, Gemcitabine, FOLFOX regimen, Placebo
Drug
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
19
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 28, 2026, 10:14 AM EDT
Completed Phase 3 Interventional

Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease Inhibitor

NCT00041769
View directory record Official record
Conditions
HIV Infections
Interventions
Therapeutic Drug Monitoring (TDM)
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
46
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2010 · Synced Oct 28, 2026, 10:14 AM EDT
Terminated Not applicable Interventional

Study to Evaluate Iovera®° in Adult Patients Undergoing Total Knee Arthroplasty

NCT04191031
View directory record Official record
Conditions
Post-Operative Pain Management
Interventions
ioveraº, ioveraº sham
Device
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
22 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Fremont, California • Pasadena, California • Tamarac, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 28, 2026, 10:14 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

NCT07219420
View directory record Official record
Conditions
Palmoplantar Pustulosis
Interventions
Bimekizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Birmingham, Alabama • Fremont, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 28, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).

NCT00863746
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Fayetteville, Arkansas • Stanford, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 28, 2026, 10:14 AM EDT
Recruiting Phase 2 Interventional

Epetraborole in Patients With Mycobacterium Abscessus Lung Disease

NCT07301320
View directory record Official record
Conditions
Mycobacterium Abscessus Infection
Interventions
Epetraborole, Placebo
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 28, 2026, 10:14 AM EDT
Not listed No phase listed Observational

Diaphragmatic Breathing Exercises in Total Knee Arthroplasty Patients

NCT04336579
View directory record Official record
Conditions
Anesthesia and Analgesia
Interventions
Diaphragmatic Breathing
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
50 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Oct 28, 2026, 10:14 AM EDT
Completed Not applicable Interventional Results available

Stress in Inflammatory Bowel Disease

NCT05202418
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Psychological
Interventions
Biofeedback Enhanced Treatment
Behavioral
Lead sponsor
Emory University
Other
Eligibility
13 Years to 18 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 28, 2026, 10:14 AM EDT
Completed Not applicable Interventional Results available

Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial

NCT02232282
View directory record Official record
Conditions
Painful Bladder Syndrome, Interstitial Cystitis
Interventions
standard acupuncture treatment, Control Sham/Minimal Acupuncture
Device
Lead sponsor
Loyola University
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 28, 2026, 10:14 AM EDT
Recruiting Not applicable Interventional

Functional Balance Intervention in Multiple Sclerosis

NCT06341023
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Functional Balance Intervention, Stretching
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 28, 2026, 10:14 AM EDT
Recruiting Phase 2 Interventional

Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation

NCT04968990
View directory record Official record
Conditions
Wilms Tumor
Interventions
Proton Beam Radiation (PBRT), DD-4A Chemotherapy Regimen, Complete Surgical Resection, Surgical Resection, Partial Nephrectomy
Device · Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 28, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00678210
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
29
States / cities
Tucson, Arizona • Little Rock, Arkansas • Oceanside, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 28, 2026, 10:14 AM EDT
Enrolling by invitation Not applicable Interventional

NQ Square TMS for MDD 1Dx3S Adults Multi-site Sham-controlled Protocol

NCT07369180
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Active Accelerated rTMS Treatment, Sham Accelerated rTMS Treatment
Device
Lead sponsor
NeuroQore Inc.
Industry
Eligibility
22 Years to 85 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Campbell, California • Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 28, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

NCT04487860
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
AS012, Placebo
Drug
Lead sponsor
Ache Laboratorios Farmaceuticos S.A.
Industry
Eligibility
18 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
19
States / cities
Phoenix, Arizona • Bryant, Arkansas • Fremont, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 28, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin

NCT00763451
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 28, 2026, 10:14 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

NCT05630885
View directory record Official record
Conditions
HIV-1-infection, Elevated Cardiovascular Risk
Interventions
CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
45 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 28, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy

NCT00688701
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Oct 28, 2026, 10:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

NCT04661839
View directory record Official record
Conditions
COVID-19
Interventions
COVID-HIGIV, Placebo (saline)
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 28, 2026, 10:14 AM EDT
Withdrawn Phase 4 Interventional

Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients

NCT02160301
View directory record Official record
Conditions
Post Operative Pain Control
Interventions
Gabapentin, Acetaminophen, Celecoxib, Dexamethasone, Oxycodone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 28, 2026, 10:14 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

NCT03896581
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
33
States / cities
Phoenix, Arizona • San Diego, California • Tustin, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 10:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Bowel Function After Minimally Invasive Urogynecologic Surgery

NCT01044212
View directory record Official record
Conditions
Functional Disorder of Intestine
Interventions
Docusate, Bowel medications
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Oct 28, 2026, 10:14 AM EDT
Withdrawn Phase 3 Interventional

Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)

NCT01870284
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Ixekizumab, Placebo, Adalimumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
34
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Upland, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 28, 2026, 10:14 AM EDT
Active, not recruiting Phase 3 Interventional

Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)

NCT03040778
View directory record Official record
Conditions
Medication-related Osteonecrosis of the Jaw, Bisphosphonate-related Osteonecrosis of the Jaw, Avascular Necrosis
Interventions
Pentoxifylline, Placebo, Tocopherol
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Birmingham, Alabama • Ann Arbor, Michigan • Lake Success, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 28, 2026, 10:14 AM EDT